RLAY Earnings & Financial Statements
Relay Therapeutics, Inc.
$17.49
+$0.43(+2.49%)
48
Overall
60
Value
30
Tech
55
Quality
Market Cap
$3.74B
Volume
847.08K
52W Range
$5.85 - $21.27
Target Price
$27.08
RLAY earnings and financial statements: Relay Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RLAY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M |
| Operating income | -$302.74M | -$372.47M | -$373.00M | -$299.27M | -$364.70M |
| EBITDA | -$272.92M | -$332.24M | -$336.70M | -$286.38M | -$223.08M |
| Net income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M |
| EPS (diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $621.33M | $871.30M | $843.98M | $1.10B | $1.01B |
| Total liabilities | $54.27M | $93.50M | $91.98M | $149.55M | $110.64M |
| Shareholders’ equity | $567.06M | $777.79M | $752.00M | $950.22M | $897.81M |
| Cash and equivalents | $84.02M | $124.29M | $143.74M | $151.79M | $280.12M |
| Long-term debt | $28.69M | $42.77M | $48.50M | $53.47M | $21.06M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$235.46M | -$249.11M | -$300.32M | -$229.49M | -$74.41M |
| Capital expenditure | -$410.0K | -$2.02M | -$4.13M | -$9.06M | -$3.47M |
| Free cash flow | -$235.87M | -$251.13M | -$304.44M | -$238.55M | -$77.88M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLAY | $17.49 | +2.5% | 847.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Relay Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW